Efficacy of Vigabatrin

Vigabatrin treatment is suitable for children with childhood spasticity (1 month to 2 years old) and may outweigh the potential risk of vision loss. As an adjuvant, it is also indicated in the response of adult patients with complex epilepsy (CPS) to several alternatives and may provide greater benefit than the risk of vision loss. Vigabatrin is not a suitable first-line drug for CPS. Available data suggest that vigabatrin is effective in the treatment of infantile spasms regardless of the underlying cause.

Vibatrin is the first therapy approved to treat infantile spasms and is an important new option as add-on therapy for approximately 30% to 36% of adult patients with refractory complex focal epilepsy, in whom seizures remain uncontrolled despite the availability of many antiepileptic therapies. Vigabatrin may cause permanent bilateral concentric visual field constriction in 30% or more of patients, ranging in severity from mild to severe, including tunnel vision within 10 degrees of visual gaze, and may result in disability. In some cases, Vibatrin can also damage the central retina, reducing vision.

The original Vigabatrin drug has not yet been launched in China, so it is not included in medical insurance. The Hong Kong version of the specificationsThe price of 500mg*100 bags per box may be more than 1,000 yuan (the price may fluctuate due to exchange rate effects). It is reported that an Indian chemical generic drug vigabatrin powder is on the domestic market. The price of each box of 500mg*50 bags may be more than 3,000 yuan. Its pharmaceutical ingredients are basically the same as those of the original drug. The Turkish version of Vigabatrin currently sold overseas may cost more than RMB 1,000 per box of 500mg*100 bags (the price may fluctuate due to exchange rates).